PCSK9 and neoplasm: DECP, by targeting PCSK9, inhibited PCSK9 activity, increasing the proportion of mature DCs, tumor‐infiltrating CD8+ T cells, and natural killer cells in HCC, while depleting Foxp3+ regulatory T cells [210].